# UZEDY (risperidone) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/risperidone

> The FDA approved UZEDY (risperidone), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on October 10, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is UZEDY (risperidone) FDA approved?

Yes. The FDA approved UZEDY (risperidone), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on October 10, 2025. Press release filed with the SEC (EX-99): "On October 10, 2025, it was announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults." [Calendar and source filings](https://sec-api.dev/pdufa/risperidone)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-381899, https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/risperidone#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | UZEDY (risperidone) |
| Codes |  |
| Sponsor | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) https://sec-api.dev/companies/teva/catalysts |
| Indications | [schizophrenia in adults](https://sec-api.dev/indications/schizophrenia-in-adults) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 15, 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22213586_2024_Orig1s000OtherActionLtrs.pdf%22

### April 28, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: schizophrenia in adults.
- First seen 2025-01-29, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213586 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name TEVA; product UZEDY (RISPERIDONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213586%22
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "On April 28, 2023, the FDA approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults, which was launched in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000493): "UZEDY was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002849): "extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/exh_991.htm

### October 10, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-09-03, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "On October 10, 2025, it was announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "On October 10, 2025, Teva and MedinCell announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1)" https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- SEC Form 10-Q (accession 0000818686-26-000006): "On October 10, 2025, we announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults." https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/teva-20260930.htm

### October 10, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213586 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name TEVA; product UZEDY (RISPERIDONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213586%22

## Same indication

- [BYSANTITM (milsaperidone)](https://sec-api.dev/pdufa/milsaperidone) (VNDA)
- [WELTRUZATM (olanzapine)](https://sec-api.dev/pdufa/olanzapine) (TEVA)
- [SZ-001](https://sec-api.dev/pdufa/sz-001) (AVXL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/risperidone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "UZEDY (risperidone) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/risperidone

```bibtex
@misc{secapidev_pdufa_risperidone_20261116,
  title        = {UZEDY (risperidone) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/risperidone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_risperidone_20261116","title":"UZEDY (risperidone) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/risperidone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
